-
3组性别差异无统计学意义(P>0.05),年龄在HC和AIS组差异亦无统计学意义(P>0.05),PSCI组年龄明显高于HC组和AIS组(P < 0.01)(见表 1)。3组高血压、糖尿病、卒中史、高血脂、同型半胱氨酸(Hcy)及NIHSS评分、BI评分、mRS、MoCA及NfL差异均有统计学意义(P < 0.01),胱抑素(Cys)差异无统计学意义(P>0.05)(见表 2)。
项目 HC组
(n=60)ASI组
(n=60)PSCI组
(n=60)χ2 P 年龄/岁 67.26±11.02 68.17±9.12 73±8.38*# 6.23△ >0.05 女性 24 (40.0) 19 (31.6) 22 (38.3) 0.92 >0.05 高血脂 3 (5.0) 18 (30.0) 18 (30.0) 14.73 < 0.01 糖尿病 3 (5.0) 22 (36.7) 36 (60.0) 40.82 < 0.01 卒中史 4 (7.8) 28 (46.7) 60 (100.0) 105.30 < 0.01 高血压史 6 (10.0) 40 (66.7) 60 (100.0) 102.62 < 0.01 △示F值。q检验:与HC组比较*P < 0.05;与AIS组比较#P < 0.05 表 1 3组一般资料[n;百分率(%)]
项目 HC组
(n=60)AIS组
(n=60)PSCI组
(n=60)F P MS组内 Hcy 10.25±7.79 18.32±5.68* 17.82±5.48* 29.93 < 0.01 40.992 Cys 3.87±15.64 4.88±6.65 5.65±23.09 0.17 >0.05 273.993 NfL 105.80±45.68 325.35±586.88* 195.67±68.38# 6.24 < 0.01 117 063.540 NIHSS 1.00±2.67 4.21±3.47* 3.07±1.68*# 21.67 < 0.01 7.331 mRS 1.00±0.50 2.38±1.35 2.89±0.83 109.8 < 0.01 0.750 MoCA 23.10±4.23 20.52±6.21* 16.43±4.83*# 25.52 < 0.01 26.595 BI 99.00±1.00 70.52±27.88 73.04±17.78 29.03 < 0.01 319.700 q检验:与HC组比较*P<0.05;与AIS组比较#P<0.05 表 2 3组生化指标及神经心理评估(x±s)
-
血清NfL与MoCA呈明显负相关关系(r=-0.707,P < 0.01),与NIHSS呈明显正相关关系(r=0.724,P < 0.01),与BI呈明显负相关关系(r=-0.67,P < 0.01),与mRS呈明显正相关关系(r=0.501,P < 0.01)。
-
根据MoCA量表将认知障碍分成轻和中重度,不同程度的认知障碍,血清NfL含量不同,认知障碍越重NfL含量越高,不同程度间差异有统计学意义(P < 0.01)(如表 3)。
分组 60 MoCA/分 NfL/pg MCI 35 22.0±1.5 176.6±125.2 PSD 25 13.9±2.7 225.0±53.0 t — 14.83 1.78 P — < 0.01 < 0.05 表 3 轻、中重度卒中后认知障碍病人血清NfL含量比较(x±s)
-
以PSCI为正值,检验结果变量的值越大,越有可能为病人,1是PSCI, 0是正常人,状态变量的值是1,ROC曲线下面积为0.81(95%CI 0.780~0.890),临界值切点是175.61,敏感性是65.5%,特异性是93.8%,ROC曲线显示血清NfL在PSCI的诊断中特异性较高。
血清神经丝蛋白轻链对卒中后认知障碍的临床意义
Clinical significance of serum neurofilament light chain on post-stroke cognitive impairment
-
摘要:
目的探讨血清神经丝轻链蛋白(NfL)与卒中后认知障碍(PSCI)的相关性及其临床意义。 方法选取正常健康体检者60名(HC组),急性缺血性脑卒中(AIS)病人60例(AIS组),利用蒙特利尔认知评估量表(MoCA)进行评定为PSCI病人60例(PSCI组),采用电化学发光免疫法检测NfL含量,并进行美国国立卫生院卒中量表(NIHSS)、MoCA、日常生活活动能力量表(Barthel index,BI)、改良Rankin量表(mRS)神经心理评估和生化指标的检测。 结果血清NfL在HC组、AIS组和PSCI组的含量有显著差异,神经系统损伤越重NIHSS评分越高,NfL含量越高(r=0.724,P < 0.01);生活自理能力越差,BI分数越低,NfL含量越高(r=-0.670,P < 0.01);认知功能越差,MoCA评分越低,NfL含量越高(r=-0.707,P < 0.01);不同认知障碍NfL含量不同,轻度认知障碍NfL含量低于中重度(P < 0.05);血清NfL含量与mRS呈正相关关系(r=0.501,P < 0.01),血清NfL含量越高,神经恢复功能越差。高脂血症、高血压史、糖尿病、卒中史差异有统计学意义(P < 0.01),生化指标中高同型半胱氨酸差异有统计学意义(P < 0.01);PSCI的NfL含量ROC曲线下面积为0.810(P < 0.01)。 结论NfL可作为早期诊断PSCI发生的生物标志物和预测PSCI严重性的新兴标志物,对PSCI的早发现、早防治具有积极的临床意义。 Abstract:ObjectiveTo investigate the correlation between serum neurofilament light chain (NfL) and post-stroke cognitive impairment (PSCI) and its clinical significance. MethodsSixty health-examination people, 60 patients with acute ischemic stroke (AIS) and 60 patients with PSCI by Montreal congnitive assessment scale(MoCA) were selected.Electrochemiluminescence was used to detect the NfL content in peripheral blood for health control (HC) group, AIS group, and PSCI group.National Institutes of Health stroke scale (NIHSS), MoCA, Barthel index(BI) and biochemical indexes, and modified rankin scale(mRS) were measured in the three groups. ResultsThere were significant differences in the levels of serum NfL in HC group, AIS group, and PSCI group.The NfL content increased with the increase of nervous system damage and NIHSS score(r=0.724, P < 0.01), increased with with the decrease of self-care ability and BI score(r=-0.670, P < 0.01), and increased with the decrease of cognitive function and MoCA score(r=-0.707, P < 0.01).The NfL content of mild cognitive impairment was lower than that of moderate and severe cognitive impairment.There was also a positive correlation between serum NfL and mRS(r=0.501, P < 0.01), The NfL content increased with the decrease of nerve recovery function.In three groups, there were significant differences in hyperlipidemia, hypertension history, diabetes, and stroke history(P < 0.01), and the difference of biochemical indicator homocysteine was statistically significant(P < 0.01).The area under receiver operating characteristic curve of NfL in PSCI was 0.810(P < 0.01). ConclusionsNfL content can be used as a biomarker for early diagnosis of PSCI and a novel predictor of the severity of PSCI, which has positive clinical significance for early detection and prevention of PSCI. -
表 1 3组一般资料[n;百分率(%)]
项目 HC组
(n=60)ASI组
(n=60)PSCI组
(n=60)χ2 P 年龄/岁 67.26±11.02 68.17±9.12 73±8.38*# 6.23△ >0.05 女性 24 (40.0) 19 (31.6) 22 (38.3) 0.92 >0.05 高血脂 3 (5.0) 18 (30.0) 18 (30.0) 14.73 < 0.01 糖尿病 3 (5.0) 22 (36.7) 36 (60.0) 40.82 < 0.01 卒中史 4 (7.8) 28 (46.7) 60 (100.0) 105.30 < 0.01 高血压史 6 (10.0) 40 (66.7) 60 (100.0) 102.62 < 0.01 △示F值。q检验:与HC组比较*P < 0.05;与AIS组比较#P < 0.05 表 2 3组生化指标及神经心理评估(x±s)
项目 HC组
(n=60)AIS组
(n=60)PSCI组
(n=60)F P MS组内 Hcy 10.25±7.79 18.32±5.68* 17.82±5.48* 29.93 < 0.01 40.992 Cys 3.87±15.64 4.88±6.65 5.65±23.09 0.17 >0.05 273.993 NfL 105.80±45.68 325.35±586.88* 195.67±68.38# 6.24 < 0.01 117 063.540 NIHSS 1.00±2.67 4.21±3.47* 3.07±1.68*# 21.67 < 0.01 7.331 mRS 1.00±0.50 2.38±1.35 2.89±0.83 109.8 < 0.01 0.750 MoCA 23.10±4.23 20.52±6.21* 16.43±4.83*# 25.52 < 0.01 26.595 BI 99.00±1.00 70.52±27.88 73.04±17.78 29.03 < 0.01 319.700 q检验:与HC组比较*P<0.05;与AIS组比较#P<0.05 表 3 轻、中重度卒中后认知障碍病人血清NfL含量比较(x±s)
分组 60 MoCA/分 NfL/pg MCI 35 22.0±1.5 176.6±125.2 PSD 25 13.9±2.7 225.0±53.0 t — 14.83 1.78 P — < 0.01 < 0.05 -
[1] 中国卒中学会. 中国卒中后认知障碍防治研究专家共识[J]. 中国卒中杂志, 2020, 15(2): 158. doi: 10.3969/j.issn.1673-5765.2020.02.010 [2] 王陇德, 王金环, 彭斌, 等. 中国脑卒中防治报告2016概要[J]. 中国脑血管病杂志, 2017, 14(4): 217. doi: 10.3969/j.issn.1672-5921.2017.04.010 [3] 中国卒中学会. 卒中后认知障碍管理专家委员会[J]. 中国卒中杂志, 2017, 12(6): 519. doi: 10.3969/j.issn.1673-5765.2017.06.011 [4] DOUIRI A, RUDD AG, WOLFE, CD. Prevalence of poststroke cognitive impairment: South London stroke register 1995-2010[J]. Stroke, 2013, 44(1): 138. doi: 10.1161/STROKEAHA.112.670844 [5] 喻才元, 何艳婷, 周宇. 神经丝轻链多肽与疾病的关系研究进展[J]. 医学综述, 2015, 21(11): 1959. doi: 10.3969/j.issn.1006-2084.2015.11.015 [6] ZETTERBERG H, SKILLEÄCK T, MATTSSON N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression[J]. JAMA Neurol, 2016, 73(1): 60. doi: 10.1001/jamaneurol.2015.3037 [7] SKILLEÄCK T, FARAHMAND B, BARTLETT JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival[J]. Neurology, 2014, 83(21): 1945. doi: 10.1212/WNL.0000000000001015 [8] SKILLEÄCK T, MATTSSON N, BLENNOWlK, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2017, 18(5/6): 397. [9] ROSENGREN LE, KARLSSON JE, KARLSSON JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF[J]. J Neurochem, 1996, 65(5): 2013. [10] PREISCHE O, SCHULTZ SA, APEL A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. J Nat Med, 2019, 25(2): 277. doi: 10.1038/s41591-018-0304-3 [11] HJALMARSSON C, BJERKE M, ANDERSSON B, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke[J]. J Cent Nerv Syst Dis, 2014, 6: 51. [12] PETZOLD A, MICHEL P, STOCK M, et al. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome[J]. J Stroke Cerebrovasc Dis, 2008, 17(4): 196. doi: 10.1016/j.jstrokecerebrovasdis.2008.02.002 [13] PUJOL-CALDER NF, PORTELIUS E, ZETTERBERG H, et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke[J]. Neurosci Lett, 2019, 698: 58. doi: 10.1016/j.neulet.2018.12.042 [14] KALARIA RN, AKINYEMI R, IHARA M. Stroke injury, cognitive impairment and vascular dementia[J]. Biochimica Et Biophysica Acta, 2016, 1862(5): 915. doi: 10.1016/j.bbadis.2016.01.015 [15] SHIM H. Vascular cognitive impairment and post-stroke cognitive deficits[J]. Curr Neurol Neurosci Rep, 2014, 14(1): 418. doi: 10.1007/s11910-013-0418-4 [16] GATTRINGER T, PIRPAMER L, HOFER E, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease[J]. Neurology, 2017, 89(20): 2108. doi: 10.1212/WNL.0000000000004645 [17] TRAENKA C, DISANTO G, SEIFFGE DJ, et al. Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection[J]. Cerebrovasc Dis, 2015(5/6), 40: 222. doi: 10.1159/000440774 [18] BERGMAN J, DRING A, ZETTERBERG H. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matterinjury in MS[J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(5): e271. doi: 10.1212/NXI.0000000000000271 [19] KUHLE J, GAIOTTINO J, LEPPERT D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome[J]. Neurol Neurosurg Psychiatry, 2015, 86(3): 273. doi: 10.1136/jnnp-2013-307454 [20] BORDET R, IHL R, KORCZYN AD. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report[J]. BMC Med, 2017, 15(1): 2. doi: 10.1186/s12916-016-0762-8 [21] LEYS D, HENON H, MACKOWIA-CORDOLIANI MA, et al. Poststroke dementia[J]. Lancet Neurol, 2005, 4(11): 752. doi: 10.1016/S1474-4422(05)70221-0 [22] MEETER LH, DOPPER EG, JISKOOT LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia[J]. Ann Clin Transl Neurol, 2016, 3(8): 623. doi: 10.1002/acn3.325 [23] PIJNENBURG YA, VERWEY NA, VAN DER FLIER WM, et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes[J]. Alzheimers Dement (Amst. ), 2015, 1(4): 505. doi: 10.1016/j.dadm.2015.11.001 [24] MATTSSON N, ANDREASSON U, ZETTERBERG H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2017, 74(5): 557. doi: 10.1001/jamaneurol.2016.6117 [25] WESTON PSJ, POOLE T, RYAN NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167. doi: 10.1212/WNL.0000000000004667 [26] SJOGREN M, BLOMBERG M, JONSSON M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes[J]. J Neurosci Res, 2001, 66(3): 510. doi: 10.1002/jnr.1242 [27] IDLAND AV, SALA-LLONCH R, BORZA T, et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults[J]. Neurobiol Aging, 2017, 49: 138. doi: 10.1016/j.neurobiolaging.2016.09.012